The Carlyle Group, a global investment firm, agreed to invest $53m in CureApp, a Japanese medical technology company. "We see tremendous growth opportunities for digital therapeutics in helping to address the growing social needs of Japan’s ageing population, to advance public health access, and to reduce overall healthcare costs through early intervention. CureApp has a distinct competitive market advantage as a leading prescription digital therapeutics company. We are excited to partner with its co-founders for Carlyle Japan’s second strategic growth investment and to help advance digital health solutions in Japan," Kazuhiro Yamada, Carlyle Managing Director and Head of Japan.